# To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject

Study · id `cardio:ct-nct02098460` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02098460](<https://clinicaltrials.gov/study/NCT02098460>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02098460

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT02098460. Randomized; triple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2016-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT02098460, source copy `cardio:ctgov-nct02098460-2025-03-27`, retrieved 2026-10-31)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT02098460, source copy `cardio:ctgov-nct02098460-2025-03-27`, retrieved 2026-10-31)
- Primary completion: 2016-03 (actual) (ClinicalTrials.gov record NCT02098460, source copy `cardio:ctgov-nct02098460-2025-03-27`, retrieved 2026-10-31)
- Completion: 2016-03 (actual) (ClinicalTrials.gov record NCT02098460, source copy `cardio:ctgov-nct02098460-2025-03-27`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT02098460, source copy `cardio:ctgov-nct02098460-2025-03-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02098460-2025-03-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject
- Condition: Severe Hypercholesterolemia
- Intervention (Drug): Atorvastatin, Probucol, Cilostazol
- Lead sponsor: Otsuka Beijing Research Institute
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Otsuka Beijing Research Institute (`cardio:org-otsuka-beijing-research-institute`)

## Provenance

Content hash: f1d761bd7138fd2e60372d4641b3f45e4fac845b891ef0124860c02870a1a9cc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
